Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially...

Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative...

CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option...

Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2...

Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated...

Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd